Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer Inc. and Astellas Pharma Inc. are conducting a significant clinical study titled ‘TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE V ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

An announcement from Astellas Pharma ( ($JP:4503) ) is now available. Pfizer and Astellas Pharma have announced positive results from their Phase ...

Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by ...

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...